Coming soon. First inventory is in final QC.Coming soon
Compliance
You must be 21 or older. Agree to the following terms before accessing product information and pricing.
Research Use Policy Summary
For laboratory research use only. Not for human or veterinary consumption, diagnostic use, therapeutic use, or clinical use.

Metabolic Research
Accept the research disclaimer to view pricing and purchase options.
Product Usage Notice · This product is intended strictly for research and laboratory use only. It is designated for in vitro testing and experimental purposes. Any use involving human or animal consumption is prohibited by law. All information provided on this website is for educational purposes only. This product must only be handled by licensed, qualified professionals. It is not intended for use as a drug, food, or cosmetic, and must not be misused, mislabeled, or misrepresented as such. Read full Research Use Policy →
Technical specifications
Retatrutide is a 39-amino acid synthetic triple incretin receptor agonist (GIP, GLP-1, glucagon) studied for simultaneous multi-receptor binding, downstream signaling crosstalk, and metabolic pathway pharmacology in in vitro and preclinical models.
Triple-Hormone-Receptor Agonist Retatrutide for Metabolic Receptor Signaling New England Journal of Medicine Published pharmacology literature examining simultaneous GIP, GLP-1, and glucagon receptor agonism and downstream incretin signaling in preclinical models. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.
View StudyRetatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for Metabolic Receptor Pharmacology The Lancet Published pharmacology literature characterizing tri-receptor binding profiles and intracellular signaling cascades in laboratory models. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.
View StudyTriple Hormone Receptor Agonist Retatrutide for Hepatic Metabolic Signaling Literature Nature Medicine Published pharmacology literature examining hepatic receptor signaling and lipid metabolism pathway modulation in preclinical systems. Cited for scientific context only; it does not provide use guidance or product claims for this research compound.
View StudyGlucagon-Based Multi-Agonist Approaches for Metabolic Pathway Literature Molecular Metabolism Preclinical characterization of LY3437943 (retatrutide) showing tri-agonism at GIP/GLP-1/glucagon receptors, studying receptor binding affinity, downstream signaling, and energy expenditure pathways in animal models.
View StudyThis compound is supplied strictly for in-vitro and preclinical research use only. Primary applications include the areas below.
Tool compound for investigating simultaneous GIP, GLP-1, and glucagon receptor engagement and intracellular signaling crosstalk in cell-based models.
Used in preclinical studies to characterize multi-receptor agonist signaling, structure-activity relationships, and hepatic lipid metabolism pathway pharmacology.
Lot records organize identity, purity, storage context, and supporting COA documentation for laboratory intake review.
Lot documentation reports 99%+ purity and identity verification by the listed analytical method.
Explore